Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.38 |
| ▸ | SELE | P16581 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888693 | 0.86 | GABRA1 (0.41) | L3MBTL1TDP1MAPTCYP2C9CYP2D6 | |
| SCHEMBL5313607 | 0.83 | CYP2C9 (0.51) | MAPTMEN1KMT2ACYP2C9CYP2D6 | |
| SCHEMBL14113377 | 0.83 | SLC6A4 (0.50) | L3MBTL1MAPTMEN1KMT2ANPSR1 | |
| SCHEMBL11121836 | 0.81 | CYP1A2 (0.53) | L3MBTL1TDP1MAPTHKDC1MEN1 | |
| SCHEMBL30548756 | 0.81 | CYP1A2 (0.53) | L3MBTL1TDP1MAPTHKDC1MEN1 | |
| SCHEMBL4808650 | 0.81 | GABRA1 (0.48) | L3MBTL1CYP1A2CYP3A4ICAM1GABRA1 | |
| SCHEMBL30389926 | 0.81 | GABRA1 (0.48) | L3MBTL1CYP1A2CYP3A4ICAM1GABRA1 | |
| SCHEMBL4801714 | 0.80 | MMP2 (0.52) | MEN1KMT2AHTR1AHTR3ADHFR | |
| SCHEMBL2887963 | 0.78 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2886389 | 0.76 | MAPT (0.51) | TDP1MAPTMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | L3MBTL1 1217/4885TDP1 4583/4885MAPT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.